Pharmadrug Inc.

PHRX

CA71716W2040

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 15:09:44 17/07/2024 BST			5-day change	1st Jan Change
0.01 ^CAD	0.00%		+100.00%	-81.82%

05-15	PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	MT
05-02	PharmaDrug Announces Directorate Changes	CI

Aura Health Corp. announced that it has received CAD 0.3 million in funding from Quinsam Capital Corporation

January 02, 2018

Aura Health Corp. announced a private placement of convertible debentures for gross proceeds of CAD 300,000 on January 3, 2018. The transaction included participation from new investor Quinsam Capital Corporation (CNSX:QCA).

Latest news about Pharmadrug Inc.

PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	05-15	MT
PharmaDrug Announces Directorate Changes	05-02	CI
PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia	05-01	MT
Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	04-16	MT
Pharmadrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine	03-13	CI
PharmaDrug Inc Announces Board Changes	02-27	CI
PharmaTher Provides Update For PD-001	02-21	MT
Pharmadrug Inc. Announces Marketing and Distribution Services Agreement with Outside the Box Capital Inc	02-12	CI
Pharmadrug Inc. announced that it has received CAD 0.326 million in funding	02-07	CI
Pharmadrug Inc. announced that it expects to receive CAD 0.326 million in funding	01-31	CI
Pharmadrug Inc. completed the acquisition of Securedose Synthetics Inc.	11-06	CI
Pharmadrug Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/10/23	CI
Pharmadrug Inc. entered into a definitive agreement to acquire Securedose Synthetics Inc. for CAD 1.1 million.	26/10/23	CI
Pharmadrug Inc. Announces CFO Changes	20/10/23	CI
PharmaDrug Inc. Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease	14/09/23	CI
PharmaDrug Inc. Announces Board Changes	06/09/23	CI
PharmaDrug Inc. Announces CEO Changes	06/09/23	CI
Pharmadrug Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/08/23	CI
Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/05/23	CI
Pharmadrug Inc. Appoints David Posner to Its Advisory Committee and as Consultant	23/05/23	CI
Pharmadrug Inc. Auditor Raises 'Going Concern' Doubt	11/05/23	CI
Pharmadrug Inc. announced that it has received CAD 0.1 million in funding	13/04/23	CI
PharmaDrug Inc. Enters into Research Collaboration Agreement with PharmaTher Holdings Ltd	22/02/23	CI
PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer	13/02/23	CI

Chart Pharmadrug Inc.

Duration

Period

More charts

Company Profile

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Companyâs subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
PHARMADRUG INC.	-81.82%	779K
MCKESSON CORPORATION	+25.55%	75.74B
CARDINAL HEALTH, INC.	-4.57%	23.24B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+17.81%	8.76B
HUADONG MEDICINE CO., LTD	-31.67%	6.69B
H. LUNDBECK A/S	+20.57%	5.58B
GALENICA AG	+4.12%	4.22B
EBOS GROUP LIMITED	-3.94%	3.99B
MEDIPAL HOLDINGS CORPORATION	+14.24%	3.39B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+10.59%	3.23B